Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2024
PHARMAGILLY from Charleroi, company number BE0859702882, closed financial year 2024 with a result of € -26,702 after tax. For that financial year PHARMAGILLY recorded a gross margin of € 120,224 and equity of € 188,605. Compared with financial year 2023, the result moved from € 33,610 to € -26,702. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 25, 2025.
€ 188,605
▼ 12% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -26,702
▼ still € 33,610 profit in 2023
Profit after tax over the fiscal year.
€ 5,106
▼ 89% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 123,518.
People and assets in 2024
1.3
Average over the fiscal year, from the social balance sheet.
€ 87,203
▲ 203% vs 2023
€ 67,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 3,692
▼ 29% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
€ 397,508
▼ 10% vs 2023
€ 46,421 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 30,644
▼ 44% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 27,997
▲ 78% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 157,275 | € 132,353 | € 135,195 | € 120,224 | ▼ 11% |
| Profit after taxes | € 21,333 | € 27,036 | € 33,610 | € -26,702 | ▼ € 60,313 |
| Equity | € 154,661 | € 181,697 | € 215,307 | € 188,605 | ▼ 12% |
| Total debts | € 708,776 | € 658,653 | € 578,198 | € 528,420 | ▼ 9% |
| Cash | € 80,990 | € 98,987 | € 46,650 | € 5,106 | ▼ 89% |
| Land & buildings | € 560,430 | € 514,091 | € 467,752 | € 421,413 | ▼ 10% |
| Retained profit | € 89,574 | € 116,610 | € 150,221 | € 123,518 | ▼ 18% |
| Bank debt | € 532,634 | € 488,262 | € 443,217 | € 397,508 | ▼ 10% |
| Balance sheet total | € 863,436 | € 840,349 | € 793,505 | € 717,024 | ▼ 10% |
| Employees (FTE) | - | - | - | 1.3 |
Key figures of PHARMAGILLY, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to PHARMAGILLY?
What happened at PHARMAGILLY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Pirot-Grosjean Management SRL stepped down as director. NBB
- New annual accounts for financial year 2024: loss of € 26,702 (▼ € 60,313 vs 2023). filed late Source: NBB ↗
- Pirot-Grosjean Management SRL became a director. NBB
- New establishment in Charleroi. KBO
- Start of the company according to the CBE. KBO
In short
From € 21,333 profit in 2021 to € 26,702 loss in 2024.
Paid € 31,820 in corporate taxes since 2021.
Best year ever: 2023, with € 33,610 profit.
On average € 92,500 of value added per employee in 2024.
A new publication or filing at PHARMAGILLY? We notify you, reason included.
Follow PHARMAGILLYDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Pirot-Grosjean Management SRL and Julien Grosjean.
Directors
According to the 2024 annual accounts
Director · represented by Pirot ELEONOR
Also active at: VITACURA, PETROSUN EUROP, LA REUNION, PHARMACIE DU MOULIN, PGHM Distribution
since 2016 · until 2028
Shareholders
Julien Grosjean
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Chaussée de Châtelet 274
6060 Charleroi
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0859.702.882
- VAT number
- BE 0859.702.882
- Registered office
- Chaussée de Châtelet 274, 6060 Charleroi
- Names & denominations
- PHARMAGILLY
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 18 July 2003
- Peppol
- Not registered
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers